<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Vink, Maarten A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-Term Follow-Up of the PASSION Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">Rates of cardiac death, myocardial infarction (MI), or target lesion revascularization in patients with acute ST-elevation MI who were treated with paclitaxel-eluting stents (PES) were similar in those who were treated with bare-metal stents at 5 years. However, there was a trend toward a higher rate of late stent thrombosis (30 days to 5 years) after treatment with PES. This article presents findings from the 5-year clinical follow-up of the Paclitaxel-Eluting Stent versus Bare-Metal Stent in Acute ST-Elevation Myocardial Infarction [PASSION] Trial.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>